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The subcutaneous implantable cardioverter-deﬁbrillator
(ICD) is becoming more widespread.1 Approved by the
Food and Drug Administration for use in the United Stated in
2012, the subcutaneous ICD is now being implanted for
primary and secondary prevention of sudden cardiac death
among individuals meeting conventional ICD implantation
criteria but who do not have an indication for cardiac
resynchronization therapy or permanent bradycardia pacing,
a preexisting unipolar pacemaker, or recurrent ventricular
tachycardia that responds to antitachycardia pacing.2–4
Although it is becoming more evident that the subcutaneous
ICD is particularly desirable in patients with venous access
issues like those with end-stage renal disease on hemodial-
ysis and in patients at an increased risk of infection, more
data on this therapy are needed, especially in relation to long-
term outcomes and how those outcomes compare with those
of transvenous ICDs.4,5 Among the clinically important
outcomes are inappropriate ICD shocks. In the pivotal
randomized clinical trials of the transvenous ICD, the rate
of inappropriate shocks was up to 25%.6–9 This rate is
concerning, given the mounting evidence that shocks—both
appropriate and inappropriate—are associated with increased
mortality and worse quality of life.9–11 The rate of inappro-
priate shocks from a subcutaneous ICD is up to 13%, and the
most common causes include oversensing as well supra-
ventricular tachycardia.5,12–13
Case report
The patient was a 58-year-old man with nonischemic
cardiomyopathy who received a primary prevention ICD in
2005 that was replaced in 2012 for low battery. On a few
occasions, the patient received ICD therapies for ventricular
tachycardia. During follow-up, the patient developed perma-
nent atrial ﬁbrillation for which he was on chronicKEYWORDS Inappropriate shocks; Subcutaneous implantable cardioverter-
deﬁbrillator; Oversensing; Atrial ﬁbrillation
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).anticoagulation with warfarin. His other cardiac medication
was carvedilol (3.125 mg twice a day). In the setting of
diabetes and hypertension, the patient developed end-stage
renal disease, for which he had to be started on hemodialysis,
and eventually had persistent methicillin-sensitive Staph-
ylococcus aureus bacteremia with sepsis, for which his
transvenous ICD had to be removed.
When the patient was screened for a subcutaneous ICD in
July 2014, he was determined to be a good candidate for one
by passing the screening in primary and secondary, but not
alternate, sensing conﬁgurations. Therefore, he underwent
subcutaneous ICD insertion. He speciﬁcally received a
Boston Scientiﬁc SQ-RX generator with a BSCI CRM
electrode, Q-TRAK. The position of the lead and the can
was deemed to be appropriate and deﬁbrillation threshold
testing during the implantation procedure showed prompt
detection of ventricular ﬁbrillation with no evidence of
undersensing, successful deﬁbrillation with a 65-joule shock,
and a shock impedance of 40 ohms. The patient was in sinus
rhythm throughout his procedure, including at the time of
deﬁbrillation threshold testing. His procedure took 2 hours
and was largely uneventful. Final programmed parameters
were as follows: the shock-only zone 220 beats per minute
(bpm)/272.7 ms 80.0 J  5 and the conditional zone 200
bpm/300 ms 80.0 J  5 with primary sensing conﬁguration.
The patient was seen in follow-up shortly after the
implantation, and his device was deemed to be functioning
normally with no evidence of undersensing or oversensing
and no need to make any changes to the programming of his
device.
The patient was in his usual state of health until April 30,
2015, when he awoke to ﬁnd his hemodialysis catheter,
which was in his right subclavian vein, completely displaced.
Thus, he presented to our emergency department, where a
new hemodialysis catheter was placed in the same vein. He
went home and did ﬁne until about 3 AM on May 2, 2015,
when as he was turning to his left side, he received an ICD
shock. There were no preceding symptoms. He presented to
our emergency department where his electrocardiogram
demonstrated atrial ﬁbrillation with a narrow QRS complex.
He was asymptomatic at the time and thereafter. Inter-
rogation of his device demonstrated undersensing of the Rpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Inappropriate shocks from a subcutaneous
implantable cardioverter-deﬁbrillator may result
from positional attenuation of the R waves that
may activate the device algorithm to increase the
amplitude of the cardiac signals, resulting in
oversensing of atrial ﬁbrillation waves.
 When a patient presents with an inappropriate
shock owing to positional attenuation of the R
waves and resultant ampliﬁcation of cardiac
signals, it is important to rule out device or lead
dislodgment or migration, pleural or pericardial
effusion, and presence of hematoma.
 When a patient presents with an inappropriate
shock owing to positional attenuation of the R
waves and resultant ampliﬁcation of cardiac
signals, it is important to perform in-depth
analyses of the vector electrograms and posture in
the sensing conﬁgurations in which the patient
passed initial screening for the device.
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with a resultant inappropriate shock (Figure 1A and B).
While he was in the emergency department, the rates for the
shock-only zone and the conditional zone were increased to
250 bpm. His anteroposterior and lateral chest radiographs
showed good device and lead placement (Figure 2A and B).
In-depth analyses of the vector electrograms in the supine
and left lateral decubitus positions were done in the primary
and secondary sensing conﬁgurations, and the same mor-
phology changes seen by the device were observed in the
same vectors on the surface electrocardiogram (Figure 3A
and B). He showed evidence of oversensing on real-time
electrograms in the emergency department and on the
inpatient ward, but he had no more shocks. The vector
electrograms were examined in the supine and sitting
positions in the alternate sensing conﬁguration; however,
the R waves were found to be too small to be processed by
the device. During his hospital stay, the patient had no
bundle branch block or interventricular conduction delay
recorded on continuous telemetry. Repeated interrogation of
his device in both supine and left lateral decubitus positions
on May 3 and May 4 showed a decrease in the R-wave
amplitude; however, no further oversensing of atrial ﬁbrilla-
tion waves occurred. On the day of discharge, the followingchanges were made to his device settings: the shock-only
zone was reduced from 250 bpm to 230 bpm and the
conditional zone was reduced from 250 bpm to 200 bpm.
With the suspicion that his R-wave attenuation may be
transient and positional, the patient was advised to avoid
lying on his left side until his next follow-up appointment in
4 weeks and while awaiting further discussion with the
engineers at Boston Scientiﬁc. The patient returned to our
clinic within about a week with another ICD shock that
occurred when the patient again had lain on his left side. The
electrograms were identical to the ones downloaded previ-
ously. The patient was again advised to avoid lying on his
left side. He has abided by this recommendation and has not
had any further shocks.Discussion
In the available literature, the rate of inappropriate shocks
from subcutaneous ICDs has been reported to be up to
13%.5,12–13 However, the somewhat small number of
patients included in published studies and the relatively
short follow-up duration call for more data on this issue.
To our knowledge, this paper is the ﬁrst to report on
inappropriate shocks in a patient with a subcutaneous ICD
resulting from positional attenuation of the R waves that
activated the algorithm to increase the amplitude of the
cardiac signals, resulting in oversensing of atrial ﬁbrillation
waves. These atrial ﬁbrillation waves were interpreted by the
device as ventricular ﬁbrillation and resulted in an inappro-
priate shock. One might wonder if more extensive testing at
baseline or during implantation might have revealed this
issue. This, however, is unlikely, as the patient did very well
for about 10 months, during which follow-up interrogations
showed no evidence of undersensing of R waves and/or
oversensing of atrial ﬁbrillation waves. The timing of the
inappropriate shocks raises a question about whether the
replacement of the patient’s hemodialysis catheter may have
led to R-wave attenuation; however, the mechanism by
which this could have happened is uncertain. Subcutaneous
edema could have been a possible mechanism. Other
potential causes that we ruled out are device/lead dislodg-
ment or migration while the patient is on his left side (a chest
radiograph in this position showed no device migration),
pleural or pericardial effusion (none present on chest radio-
graph or echocardiogram), and presence of hematoma
(patient had no clinical evidence of that).
An important question is whether periodic deﬁbrillation
threshold testing during follow-up may be helpful in reveal-
ing inappropriate sensing. However, this certainly has not
Figure 1 A: Device settings and electrogram of inappropriate implantable cardioverter-deﬁbrillator (ICD) shock. B: A zoomed-in image of electrogram that
shows R-wave attenuation with undersensing and resultant oversensing of atrial ﬁbrillation waves and inappropriate ICD shock.
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Figure 2 A: Patient’s posteroanterior chest radiograph. B: Patient’s lateral chest radiograph.
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are largely questionable. Another vital consideration is
whether the detection algorithm in the device itself couldbe optimized to prevent such events from occurring. To that
end, we contacted the subcutaneous ICD engineers at Boston
Scientiﬁc to make them aware of this case.
Figure 3 In-depth analyses of the vector electrograms and posture (A: electrocardiogram [ECG] in supine position; B: ECG in left decubitus position) in the
primary sensing conﬁguration demonstrated that the morphology shift seen by the subcutaneous implantable cardioverter-deﬁbrillator is consistent with what is
seen in the same vector on the surface ECG.
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Inappropriate ICD shocks have a negative impact on patient
outcomes. As a result, every attempt should be made to
reduce the risk of inappropriate shocks. Better understanding
of reasons for these shocks is important. To that end,
clinicians should be aware of the possibility of R-wave
attenuation and oversensing of atrial ﬁbrillation as a cause of
inappropriate shocks in subcutaneous ICDs that might be
avoided by lifestyle modiﬁcations until more information
emerges on how and whether further optimization of
detection algorithms may result in a lower risk of inappro-
priate shocks.
References
1. Friedman DJ, Parzynski C, Curtis J, Varosy P, Russo A, Prutkin J, Patton K,
Mithani A, Al-Khatib SM. Early use of the subcutaneous implantable cardi-
overter deﬁbrillator in the United States: a report from the National Cardiovas-
cular Data Registry [abstract]. J Am Coll Cardiol 2016;67:685.
2. FDA approves ﬁrst subcutaneous heart deﬁbrillator. 2012. Available at: 〈http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321755.htm〉.
Accessed June 30, 2015.
3. Subcutaneous implantable deﬁbrillator (s-icd) system - p110042. 2014. Available
at: 〈http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/Devi
ceApprovalsandClearances/Recently-ApprovedDevices/ucm326541.htm〉.
Accessed June 30, 2015.
4. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable
cardioverter-deﬁbrillator. N Engl J Med 2010;363:36–44.
5. Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, Rashtian M,
Kremers M, Crozier I, Lee KL, Smith W, Burke MC. Safety and efﬁcacy of atotally subcutaneous implantable-cardioverter deﬁbrillator. Circulation 2013;128:
944–953.
6. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP,
Higgins SL, Brown MW, Andrews ML. for the Multi-center Automatic
Deﬁbrillator Implantation Trial II Investigators. Prophylactic implantation of a
deﬁbrillator in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med 2002;346(12):877–883.
7. Bardy GH, Lee KL, Mark DB, et al. for the Sudden Cardiac Death in HF Trial
(SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-
deﬁbrillator for congestive HF. N Engl J Med 2005;352:225–237.
8. Exner DV, Pinski SL, Wyse DG, Renfroe EG, Follmann D, Gold M, Beckman KJ,
Coromilas J, Lancaster S, Hallstrom AP. AVID Investigators. Antiarrhythmics
versus implantable deﬁbrillators. Electrical storm presages nonsudden death: the
antiarrhythmics versus implantable deﬁbrillators (AVID) trial. Circulation
2001;103:2066–2071.
9. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of
deﬁbrillator shocks in patients with heart failure. N Engl J Med 2008;359:
1009–1017.
10. Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences
in effects of electrical therapy type for ventricular arrhythmias on mortality
in implantable cardioverter-deﬁbrillator patients. Heart Rhythm 2010;7:
353–360.
11. Noyes K, Corona E, Veazie P, Dick AW, Zhao H, Moss AJ. Examination of the
effect of implantable cardioverter-deﬁbrillators on health-related quality of life:
based on results from the Multicenter Automatic Deﬁbrillator Trial-II. Am J
Cardiovasc Drugs 2009;9(6):393–400.
12. Burke MC, Gold MR, Knight BP, et al. Safety and efﬁcacy of the totally
subcutaneous implantable deﬁbrillator 2-year results from a pooled analysis
of the IDE study and EFFORTLESS Registry. J Am Coll Cardiol 2015;65:
1605–1615.
13. Olde Nordkamp LR, Brouwer TF, Barr C, Theuns DA, Boersma LV, Johansen JB,
Neuzil P, Wilde AA, Carter N, Husby M, Lambiase PD, Knops RE. Inappropriate
shocks in the subcutaneous ICD: incidence, predictors and management. Int J
Cardiol 2015;195:126–133.
